Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis I: Introduction01:21

Myocarditis I: Introduction

9
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
9
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

914
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
914
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

259
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
259
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

966
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
966
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

192
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
192

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Asia-Pacific League of Associations for Rheumatology Consensus Recommendations on the Management of Juvenile Idiopathic Arthritis (JIA): Polyarticular Course JIA, Temporomandibular Joint Arthritis, Imaging, and Non-Pharmacologic Therapies.

International journal of rheumatic diseases·2026
Same author

Our Three Musketeers: A Case Series of NLRP-3 Associated Cryopyrinopathies.

Mediterranean journal of rheumatology·2025
Same author

Comparative efficacy of intravenous cyclophosphamide, mycophenolate mofetil, and tacrolimus as induction therapy for lupus nephritis: A randomized controlled open-label trial.

Lupus·2025
Same author

Modern-day limeys: Clinical, laboratory, and radiological profile of 10 paediatric scurvy patients.

Journal of family medicine and primary care·2024
Same author

LPIN2 -related Majeed syndrome: report of two Indian patients with novel variants in LPIN2 and review of literature.

Clinical dysmorphology·2023
Same author

COVID-19 related multisystem inflammatory syndrome in children (MIS-C): a hospital-based prospective cohort study from Kerala, India.

BMJ paediatrics open·2021

Related Experiment Video

Updated: Jul 11, 2025

Immunolabelling Myofiber Degeneration in Muscle Biopsies
06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

8.9K

Idiopathic Inflammatory Myopathies.

Suma Balan1, Sumanth Madan2

  • 1Department of Rheumatology and Clinical Immunology, Amrita Institute of Medical Sciences and Research Centre, Ponekkara, Kochi, Kerala, 682 041, India. sumabalan@googlemail.com.

Indian Journal of Pediatrics
|November 3, 2023
PubMed
Summary
This summary is machine-generated.

Juvenile dermatomyositis (JDM) is a complex autoimmune disease causing muscle weakness in children. Early diagnosis and multidisciplinary care, including corticosteroids and methotrexate, improve outcomes and reduce complications.

Keywords:
CalcinosisInflammatory myositisJuvenile dermatomyositisMyositis autoantibodiesVasculopathy

More Related Videos

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
09:01

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

14.2K
Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.4K

Related Experiment Videos

Last Updated: Jul 11, 2025

Immunolabelling Myofiber Degeneration in Muscle Biopsies
06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

8.9K
Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
09:01

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

14.2K
Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.4K

Area of Science:

  • Rheumatology
  • Pediatric Autoimmunology

Background:

  • Idiopathic inflammatory myopathies (IIMs) encompass autoimmune diseases causing muscle inflammation and weakness.
  • Juvenile dermatomyositis (JDM) is the most common IIM in children, differing from adult dermatomyositis (DM) with higher relapse rates and unique complications.
  • Complications in JDM include vasculopathy, lipodystrophy, insulin resistance, and calcinosis, impacting long-term health.

Purpose of the Study:

  • To review the current understanding of JDM pathogenesis, clinical course, and treatment strategies.
  • To highlight the importance of myositis autoantibodies in predicting disease course and therapeutic response.
  • To emphasize the necessity of a multidisciplinary approach for optimal JDM management.

Main Methods:

  • Literature review of idiopathic inflammatory myopathies, focusing on JDM.
  • Analysis of clinical associations of myositis-specific and -associated autoantibodies.
  • Synthesis of current therapeutic guidelines and management strategies for JDM.

Main Results:

  • JDM presents with distinct features compared to adult DM, including frequent relapses and specific long-term complications.
  • Myositis autoantibodies offer valuable insights into disease phenotype, progression, and treatment responsiveness.
  • Advances in understanding JDM have led to improved therapeutic strategies and patient outcomes.

Conclusions:

  • Effective JDM management requires early recognition and prompt referral to specialized centers.
  • A combination of corticosteroids and methotrexate is the standard first-line treatment.
  • Targeted immunosuppressive therapies and a multidisciplinary approach are crucial for refractory cases and comprehensive care.